{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T21:51:46Z","timestamp":1791582706504,"version":"4.3.4"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,6,30]],"date-time":"2023-06-30T00:00:00Z","timestamp":1688083200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004914","name":"Ferring Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004914","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine & Pharmacotherapy"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.biopha.2023.115116","type":"journal-article","created":{"date-parts":[[2023,7,6]],"date-time":"2023-07-06T08:39:31Z","timestamp":1688632771000},"page":"115116","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Partial vasopressin 1a receptor agonism reduces portal hypertension and hyperaldosteronism and induces a powerful diuretic and natriuretic effect in rats with cirrhosis and ascites"],"prefix":"10.1016","volume":"165","author":[{"given":"Guillermo","family":"Fern\u00e1ndez-Varo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9376-0214","authenticated-orcid":false,"given":"Wladimiro","family":"Jim\u00e9nez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Cable","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pere","family":"Gin\u00e8s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geoff","family":"Harris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stan","family":"Bukofzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.biopha.2023.115116_bib1","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1002\/hep.31884","article-title":"Diagnosis, evaluation, and management of ascites, spontaneous bacterial peritonitis and hepatorenal syndrome: 2021 Practice Guidance by the American Association for the Study of Liver Diseases","volume":"74","author":"Biggins","year":"2021","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.biopha.2023.115116_bib2","first-page":"23","article-title":"Hepatorenal syndrome","volume":"4","author":"Gin\u00e8s","year":"2018","journal-title":"Rev. Nat. Rev. Dis. Prim."},{"issue":"1","key":"10.1016\/j.biopha.2023.115116_bib3","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1002\/hep.28250","article-title":"Vasopressin 1a receptor partial agonism increases sodium excretion and reduces portal hypertension and ascites in cirrhotic rats","volume":"63","author":"Fern\u00e1ndez-Varo","year":"2016","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.biopha.2023.115116_bib4","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1136\/gutjnl-2011-300157","article-title":"Satavaptan for the management of ascites in cirrhosis: efficacy and safety across the spectrum of ascites severity","volume":"61","author":"Wong","year":"2012","journal-title":"Gut"},{"key":"10.1016\/j.biopha.2023.115116_bib5","first-page":"55","article-title":"Management of refractory cirrhotic ascites: challenges and solutions","volume":"10","author":"Fukui","year":"2018","journal-title":"Hepat. Med"},{"key":"10.1016\/j.biopha.2023.115116_bib6","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1677\/joe.0.1560223","article-title":"Structural bases of vasopressin\/oxytocin receptor function","volume":"156","author":"Barberis","year":"1998","journal-title":"J. Endocrinol."},{"issue":"4","key":"10.1016\/j.biopha.2023.115116_bib7","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1111\/joim.12645","article-title":"Vasopressin: physiology, assessment, and osmosensation","volume":"282","author":"Bankir","year":"2017","journal-title":"J. Intern. Med."},{"issue":"Suppl 3","key":"10.1016\/j.biopha.2023.115116_bib8","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1111\/j.1365-2036.2004.02115.x","article-title":"Review article: pharmacological treatment of hepatorenal syndrome","volume":"20","author":"Gin\u00e8s","year":"2004","journal-title":"Aliment Pharmacol. Ther."},{"issue":"5","key":"10.1016\/j.biopha.2023.115116_bib9","first-page":"380","article-title":"Cutaneous necrosis secondary to terlipressin therapy. A rare but serious side effect. Case report and literature review","volume":"109","author":"Iglesias-Juli\u00e1n","year":"2017","journal-title":"Revisit. Esp. Enferm. Dig."},{"key":"10.1016\/j.biopha.2023.115116_bib10","doi-asserted-by":"crossref","first-page":"5","DOI":"10.12659\/AJCR.913150","article-title":"Terlipressin-induced peripheral cyanosis in a patient with liver cirrhosis and hepatorenal syndrome","volume":"20","author":"Chiang","year":"2019","journal-title":"Am. J. Case Rep."},{"key":"10.1016\/j.biopha.2023.115116_bib11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2147\/JEP.S146034","article-title":"In vitro binding and receptor-mediated activity of terlipressin at vasopressin receptors V1 and V2","volume":"10","author":"Jamil","year":"2017","journal-title":"J. Exp. Pharm."},{"key":"10.1016\/j.biopha.2023.115116_bib12","doi-asserted-by":"crossref","first-page":"F1295","DOI":"10.1152\/ajprenal.90407.2008","article-title":"Effects of terlipressin on the aquaretic system: evidence of antidiuretic effects","volume":"295","author":"Krag","year":"2008","journal-title":"Am. J. Physiol. Ren. Physiol."},{"key":"10.1016\/j.biopha.2023.115116_bib13","unstructured":"Wisniewski K., Alagarsamy S., Taki H., et al. Synthesis and biological activity of terlipressin and its putative metabolites (Conference Paper). Understanding Biology Using Peptides, American Peptide Society, 2005."},{"key":"10.1016\/j.biopha.2023.115116_bib14","unstructured":"Bukofzer S., Harris G., Cable E.E. OCE-205 in rats and non-human primates: pharmacokinetic and pharmacodynamic analysis. Submitted, Curr Res Pharmacol Drug Discov."},{"issue":"1","key":"10.1016\/j.biopha.2023.115116_bib15","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1177\/0976500X231175220","article-title":"Selective partial agonism of vasopressin 1a receptors in vitro by OCE-205. In press","volume":"14","author":"Croston","year":"2023","journal-title":"J. Pharmacol. Pharmacother."},{"issue":"3","key":"10.1016\/j.biopha.2023.115116_bib16","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1006\/jtbi.1996.0130","article-title":"Rational design of receptor partial agonists and possible mechanisms of receptor partial activation: a theory","volume":"181","author":"Zhu","year":"1996","journal-title":"J. Theor. Biol."},{"issue":"2","key":"10.1016\/j.biopha.2023.115116_bib17","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.jhep.2020.04.011","article-title":"Animal models for liver disease\u2013A practical approach for translational research","volume":"73","author":"Nevzorova","year":"2020","journal-title":"J. Hepatol."},{"issue":"5","key":"10.1016\/j.biopha.2023.115116_bib18","doi-asserted-by":"crossref","first-page":"G449","DOI":"10.1152\/ajpgi.00199.2012","article-title":"Animal models of chronic liver diseases","volume":"304","author":"Liu","year":"2013","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"issue":"1","key":"10.1016\/j.biopha.2023.115116_bib19","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1111\/j.1440-1746.1992.tb00940.x","article-title":"Carbon tetrachloride induced cirrhosis in rats: a useful tool for investigating the pathogenesis of ascites in chronic liver disease","volume":"7","author":"Jim\u00e9nez","year":"1992","journal-title":"J. Gastroenterol. Hepatol."},{"issue":"4","key":"10.1016\/j.biopha.2023.115116_bib20","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1002\/hep.22170","article-title":"Hemodynamic effects of urotensin II and its specific receptor antagonist palosuran in cirrhotic rats","volume":"47","author":"Trebicka","year":"2008","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.biopha.2023.115116_bib22","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1136\/gut.10.6.433","article-title":"Radiological determination of spleen size","volume":"10","author":"Blendis","year":"1969","journal-title":"Gut"},{"key":"10.1016\/j.biopha.2023.115116_bib23","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1093\/cvr\/4.1.44","article-title":"The comparative measurement of splenic blood flow using 133 Xenon and an electromagnetic flowmeter","volume":"4","author":"Blendis","year":"1970","journal-title":"Cardiovasc Res"},{"issue":"8","key":"10.1016\/j.biopha.2023.115116_bib24","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1038\/ki.2010.4","article-title":"Afferent mechanisms of sodium retention in cirrhosis and hepatorenal syndrome","volume":"77","author":"Oliver","year":"2010","journal-title":"Kidney Int"},{"issue":"8","key":"10.1016\/j.biopha.2023.115116_bib25","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1080\/00365520902912555","article-title":"Ascites: pathogenesis and therapeutic principles","volume":"44","author":"M\u00f8ller","year":"2009","journal-title":"Scand. J. Gastroenterol."},{"issue":"13","key":"10.1016\/j.biopha.2023.115116_bib26","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1056\/NEJMra0809139","article-title":"Renal failure in cirrhosis","volume":"361","author":"Gin\u00e8s","year":"2009","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.biopha.2023.115116_bib27","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1006\/bbrc.1994.2150","article-title":"Cloning, functional expression and tissue distribution of human cDNA for the vascular-type vasopressin receptor","volume":"203","author":"Hirasawa","year":"1994","journal-title":"Biochem Biophys. Res Commun."},{"issue":"9","key":"10.1016\/j.biopha.2023.115116_bib28","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1097\/00004872-198809000-00006","article-title":"Pressure natriuresis and control of arterial pressure during chronic norepinephrine infusion","volume":"6","author":"Hall","year":"1988","journal-title":"J. Hypertens."},{"key":"10.1016\/j.biopha.2023.115116_bib29","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/3959087","article-title":"Angiotensin II-induced hypertension is attenuated by overexpressing copper\/zinc superoxide dismutase in the brain organum vasculosum of the lamina terminalis","volume":"2016","author":"Collister","year":"2016","journal-title":"Oxid. Med Cell Longev."},{"issue":"5","key":"10.1016\/j.biopha.2023.115116_bib30","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1080\/14740338.2020.1734558","article-title":"Development of hyponatremia after terlipressin in cirrhotic patients with acute gastrointestinal bleeding: a retrospective multicenter observational study","volume":"19","author":"Xu","year":"2020","journal-title":"Expert Opin. Drug Saf."},{"issue":"10","key":"10.1016\/j.biopha.2023.115116_bib31","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002930","article-title":"Desmopressin and the risk of hyponatremia: a population-based cohort study","volume":"16","author":"Fralick","year":"2019","journal-title":"PLoS Med"},{"key":"10.1016\/j.biopha.2023.115116_bib32","first-page":"F18","article-title":"Symptomatic hyponatremia in rats: effect of treatment on mortality and brain lesions","volume":"257","author":"Ayus","year":"1989","journal-title":"Am. J. Physiol."}],"container-title":["Biomedicine & Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332223009071?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332223009071?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T07:31:15Z","timestamp":1777879875000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332223009071"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":31,"alternative-id":["S0753332223009071"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2023.115116","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Partial vasopressin 1a receptor agonism reduces portal hypertension and hyperaldosteronism and induces a powerful diuretic and natriuretic effect in rats with cirrhosis and ascites","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2023.115116","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"115116"}}